Windward Bio raised $165 million in a financing designed to carry its long-acting anti-TSLP antibody into phase 3 testing for asthma. The company’s approach targets twice-yearly dosing as a potential differentiator in a crowded respiratory market, adding to momentum around longer-interval biologics aimed at improving adherence and clinic workflow.